logo
Carol Downer, Feminist Leader in Women's Health, Dies at 91

Carol Downer, Feminist Leader in Women's Health, Dies at 91

New York Times26-01-2025

Carol Downer, a leader in the feminist women's health movement who drew national fame for her role in a case known as the Great Yogurt Conspiracy — so named because she was charged with practicing medicine without a license for dispensing yogurt to treat a yeast infection — died on Jan. 13 in Glendale, Calif. She was 91.
Her death, in a hospital, was confirmed by her daughter Angela Booth, who said she had suffered a heart attack a few weeks earlier.
Ms. Downer was a self-described housewife and the mother of six in the late 1960s when she joined the women's movement and began to work on the abortion committee of her local chapter of the National Organization for Women. Years earlier, she had had an illegal abortion, and she was determined that others should not suffer as she did.
A psychologist named Harvey Karman had refined a technique for performing an abortion by suctioning the lining of a women's uterus. It was safer, quicker and less painful than the more traditional dilation and curettage technique, and he was using it to perform early-term abortions and teaching doctors how to use it.
Ms. Downer and others thought the technique was so simple that it could be performed without medical training. They learned to practice the procedure themselves.
Lorraine Rothman, another member of NOW, refined Mr. Karman's device into a kit she patented called the Del-Em, which included a flexible tube, a syringe and a jar. Doctors called the technique a vacuum extraction. The women called it a menstrual extraction — it was also a way to to regulate menstrual flow — as a kind of linguistic feint.
Ms. Downer set out to explain its use to a group of women at a feminist bookstore in Venice Beach. As she later recalled, when she began to describe the technique, which involved inserting the tube into the cervix, she realized that she was losing her audience. They were horrified. This was the era of back-room abortions, when women were dying from unsafe procedures, and here she was hawking what seemed to be an even more suspect practice.
So she changed tactics. She lay down on a table, hiked up her skirt, inserted a speculum into her vagina and invited her audience to look. The conversation veered from do-it-yourself abortions to an anatomy lesson.
The women had never seen inside their own vaginas — it was not the habit of male gynecologists in those days to educate their patients about their own anatomy — and it was an 'aha' moment for Ms. Downer. Like many women around the country — notably those in the Boston Women's Health Book Collective, who would go on to produce the self-help bible 'Our Bodies, Ourselves' — she became determined to teach women about their reproductive health.
She and Ms. Rothman toured the country demonstrating cervical exams — and menstrual extraction. They so impressed the prominent anthropologist Margaret Mead that she declared the practice one of the most original ideas of the 20th century.
'The idea of women being able to control their own birthrate is fundamental. It goes right to the heart of women's political situation,' Ms. Downer told The Los Angeles Times when Ms. Rothman died in 2007. 'We both wanted to turn the whole thing upside down. We wanted to make women equal with men.'
They opened their first clinic in Los Angeles in 1971. The next year, the police raided the place and confiscated, among other things, a tub of strawberry yogurt. As the story goes, a clinic worker protested: 'You can't have that. That's my lunch!'
Ms. Downer and a colleague, Carol Wilson, were charged with practicing medicine without a license. Ms. Downer's crime was her yogurt treatment, and Ms. Wilson's was that she had fitted a woman with a diaphragm. Ms. Wilson was also charged with performing a menstrual extraction, conducting pregnancy testing and giving a pelvic exam. She pleaded guilty to the diaphragm charge and received a fine and probation.
Ms. Downer decided to fight the yogurt charge. Using yogurt to treat a yeast infection, her defense claimed, was an old folk remedy, and in any case a yeast infection was so common that it did not require a doctor's diagnosis. The jury agreed, and as Judith A. Houck, a gender and women's studies professor, recounted in 'Looking Through the Speculum: Examining the Women's Health Movement' (2024), the male foreman sent Ms. Downer a note of appreciation.
'Carol — You're not a downer, you're a real upper!' he wrote. 'Good Luck!'
The Great Yogurt Conspiracy helped popularize women's clinics, which were sprouting up all over the country. Though many in the women's health movement were also working to eliminate gender bias in the medical profession, particularly with regard to reproductive health, and to help those who needed it most gain access to medical services, Ms. Downer remained leery of what she felt was a patriarchal institution incapable of reform. She was not convinced that change was possible.
She and others went on to found the nonprofit Federation of Feminist Women's Health Centers, and she continued to research the ways women could manage their own fertility.
Yet many feminists, abortion rights supporters and medical professionals were more than uncomfortable with Ms. Downer and Ms. Rothman's teaching; they were deeply opposed to having laypeople practice the procedure.
'Carol Downer demonstrated a very reckless form of courage and defiance,' Phyllis Chesler, the feminist psychologist, activist and author, said in an interview. 'I had a problem with the paranoia around the medical profession, and although I of course harbored a similar distrust, I didn't think it was safe or wise to put abortions in the hands of amateurs.'
In the years after the Roe v. Wade decision guaranteed a woman's constitutional right to an abortion, vacuum extraction, the technique devised by Mr. Karman, became the most common surgical procedure used by doctors to end a pregnancy. It still is, said Dr. Louise P. King, assistant professor of obstetrics, gynecology and reproductive biology at Harvard Medical School. The technique, she added, is safe when practiced by a medical professional.
'There are risks and complications if it's done wrong, notably uterine perforation,' she said in an interview, 'which is what we train not to do. I'm fully in support of those who want to take control of their health and their lives, and it saddens me to think people might have to turn to these methods without the help of professionals, that they might not have access to these professionals.'
In 1993, Ms. Downer and Rebecca Chalker, an abortion counselor, published 'A Woman's Book of Choices: Abortion, Menstrual Extraction, RU-486,' essentially a consumer guide to abortion.
Le Anne Schreiber, writing in The New York Times Book Review, called it 'a print hotline in a time of government-ordered gag rules' as well as 'a warning sign.'
'When so few doctors perform abortions," she wrote, 'when so few medical schools teach the techniques, when so many states seek to impose so many restrictions, women reluctantly begin to take risks that other people call choices.'
Carollyn Aurilla Chatham was born on Oct. 9, 1933, in Shawnee, Okla., and grew up there and in Glendale. Her father, Meade Chatham, was a clerk in a gas company; her mother, Nell (Stell) Chatham, was a secretary.
Carol studied sociology at the University of California, Los Angeles, but dropped out during her first year when she was pregnant with her first child. Her husband, Earle Wallace Brown, stayed in college and worked as a cabdriver and then a special-education teacher before contracting tuberculosis.
The family spent a year on welfare, an experience that Ms. Downer later said politicized her. Unlike most welfare recipients, she and her husband had additional support. They lived rent free in a house owned by her parents, and they received financial help from his parents and fellow teachers.
'I began to gradually develop a radical political consciousness,' she said in an oral history conducted by the Veteran Feminists of America in 2021. 'I mainly learned that no one survives on welfare without some kind of informal support network or a hustle.'
She had four children and was separated from her husband when she became pregnant, and decided to have an abortion. It was 1962, five years before abortion was legalized in California and 11 years before Roe. While the procedure was performed by a someone with experience and was medically safe, she received no anesthesia so that if the place — an office with no furniture beside a table — was raided by the police, she could get up and run.
In addition to Ms. Booth, Ms. Downer, who lived in Los Angeles, is survived by two other daughters, Laura Brown and Shelby Coleman; two sons, David Brown and Frank Downer Jr.; eight grandchildren; and several great-grandchildren. Her second husband, Frank Downer, whom she married in 1965 after her divorce from Mr. Brown, died in 2012. A daughter, Victoria Siegel, died in 2021.
Ms. Downer went back to school in the late 1980s. After earning a degree from Whittier Law School, in Costa Mesa, Calif., in 1991, she practiced immigration and employment law.
'There's a through line from Carol Downer to the current reproductive rights and reproductive justice activists,' said Dr. Houck, the author of 'Looking Through the Speculum.' 'Hers was a form of activism where women could use their heads, their hands and their hearts.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

Yahoo

time4 days ago

  • Yahoo

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

-- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD™ study of del-brax 2mg/kg every six weeks -- -- Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET -- SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced the accelerated approval regulatory pathway in the United States is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (FSHD). Additionally, the Company announced that it has initiated its global, confirmatory, Phase 3 FORWARD™ study intended to support a subsequent full approval package for del-brax for people living with FSHD in the U.S. and additional countries around the world. Del-brax is the first investigational therapy designed to treat the underlying cause of FSHD by directly targeting the disease-causing gene, double homeobox 4 (DUX4). Currently, there are no approved therapies for the treatment of FSHD, a rare, hereditary disorder marked by life-long, relentless loss of muscle strength and function, significant pain, fatigue, and progressive disability. FSHD affects approximately 45,000 to 87,000 people in the United States and Europe. "Our regulatory and clinical development progress announced today reflect our continued leadership in rare neuromuscular diseases and bring us a step closer to providing a treatment option to the FSHD community that could meaningfully impact their disease," said Sarah Boyce, president and chief executive officer at Avidity. "We have confirmed with the FDA that the accelerated approval pathway is open for del-brax. In addition, we have initiated our global confirmatory Phase 3 study intended to support our global approval strategy for del-brax." In addition to the standard guidance for the accelerated approval pathway, the company has been given detailed direction by FDA on the necessary validation steps for the surrogate biomarker. FDA's Accelerated Approval Program was instituted to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. To support full approval Avidity has initiated FORWARD, a global, confirmatory, Phase 3, randomized, placebo-controlled, double-blind, 18-month study designed to evaluate 2mg/kg of del-brax every six weeks in approximately 200 people (ages 16-70) living with FSHD in North America, Europe and Japan. FORWARD is designed to assess key FSHD-related endpoints that measure functional mobility (10MWRT and TUG), strength (QMT) and patient-reported outcomes. The flexible design of FORWARD allows the Company to gather additional data from the ongoing FORTITUDE™ biomarker cohort and elevate any of these measures to the primary endpoint. Currently, QMT is assigned as the primary endpoint. "People living with FSHD experience severe and unpredictable muscle loss, along with the constant uncertainty of how the disease will progress," said Mark Stone, CEO of FSHD Society. "We are grateful to Avidity for their innovative approach that takes into account feedback from our community, specifically in the development of a biomarker that provides insights into the real, whole-body burden of FSHD. This research enables the pursuit of a regulatory pathway that may make del-brax available to the FSHD community more quickly. This progress, along with the initiation of the FORWARD Phase 3 study and the stellar del-brax data from FORTITUDE, offers real hope for those urgently needing treatment options." Video Webcast InformationThe Company is hosting an investor and analyst event today, June 9, 2025 at 8:00 a.m. ET. Avidity management will be joined by Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE™ trial investigator, to discuss these updates relating to del-brax in FSHD. The virtual event will be available via a live video webcast and can be accessed here or from the "Events and Presentations" page in the "Investors" section of Avidity's website. A replay of the webcast will be archived on Avidity's website following the event. About the Phase 3 FORWARD™ TrialFORWARD™ is a global, confirmatory Phase 3, randomized, placebo-controlled, double-blind, 18-month study designed to evaluate delpacibart braxlosiran (del-brax) in approximately 200 people (ages 16-70) living with FSHD. The trial will be conducted at approximately 45 global sites including in the U.S., Canada, Europe and Japan. Patients will be administered either 2 mg/kg of del-brax or placebo (1:1) every six weeks. Following regulatory alignment, FORWARD is designed to be a confirmatory study to support potential full approval of del-brax. FORWARD is assessing the impact of del-brax on key FSHD-related endpoints that measure functional mobility (10-Meter Walk-Run test, or 10 MWRT, and Timed Up and Go, or TUG), strength (quantitative muscle testing, or QMT, total score), patient-reported outcomes (PROs) and decrease in KHDC1L, a novel, circulating biomarker. All study participants, regardless of whether they receive active treatment or placebo, will have the option to enroll into an open-label extension trial. For more information about the FORWARD trial, visit the FORWARD study website. About the Phase 1/2 FORTITUDE™ and Phase 2 FORTITUDE-OLE™ trialsThe FORTITUDE™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial designed to evaluate single and multiple doses of delpacibart braxlosiran or del-brax in 90 participants with facioscapulohumeral muscular dystrophy (FSHD). FORTITUDE is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of del-brax administered intravenously. Activity of del-brax is being assessed using key biomarkers, including DUX4-regulated muscle and circulating biomarkers and magnetic resonance imaging (MRI) measures of muscle volume and composition. Though the Phase 1/2 trial is not statistically powered to assess functional benefit, it explores the clinical activity of del-brax including measures of functional mobility and muscle strength as well as patient reported outcomes and quality of life measures. The trial has a total of three dose cohorts. The first two dose escalation cohorts evaluated 2 mg/kg or 4 mg/kg of del-brax versus placebo and were designed to assess safety as well as inform the dose and dose regimen of del-brax for additional studies. Avidity has completed enrollment in the dose escalation cohorts and identified 2 mg/kg every six weeks of del-brax as the dose for future clinical trials. The third, ongoing biomarker cohort in the FORTITUDE trial assesses the impact of del-brax 2 mg/kg every six weeks versus placebo for 12 months in people living with FSHD, ages 16-70. The primary endpoint of the biomarker cohort is reduction of KHDC1L, a novel DUX4-regulated circulating biomarker. Enrollment in the biomarker cohort is complete and blinded treatment is ongoing. Participants who complete FORTITUDE have the option to enroll in the ongoing FORTITUDE open-label extension (FORTITUDE-OLE™) study evaluating the long-term safety and tolerability of del-brax in participants living with FSHD. For more information about the FORTITUDE trial, visit the FORTITUDE study website or visit and search for NCT05747924. For more information on the FORTITUDE-OLE study click here or visit and search for NCT06547216. About Del-brax Del-brax is designed to treat the underlying cause of FSHD, which is caused by the abnormal expression of a gene called double homeobox 4 or DUX4. The abnormal expression of DUX4 protein leads to changes in gene expression in muscle cells that are associated with the life-long, progressive loss of muscle function in patients with FSHD. Del-brax aims to reduce the expression of DUX4 mRNA and DUX4 protein in muscles in people with FSHD. Del-brax consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DUX4 mRNA. Del-brax is currently in registrational-stage studies including FORTITUDE biomarker cohort and the global, confirmatory, Phase 3 FORWARD trial in individuals with FSHD. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Orphan designation for del-brax and the FDA has granted del-brax Fast Track designation. About Facioscapulohumeral Muscular Dystrophy (FSHD)Facioscapulohumeral muscular dystrophy (FSHD) is a rare, progressive, and variable hereditary muscle-weakening condition marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability. It is characterized by progressive and often asymmetric skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk and progresses to weakness in muscles in the lower body. FSHD is an autosomal dominant disease caused by the aberrant expression of the DUX4 (double homeobox 4) gene in the skeletal muscle, which activates genes that are toxic to muscle cells and leads to a series of downstream events that result in skeletal muscle wasting and compromised muscle function. Skeletal muscle weakness results in physical limitations throughout the whole body, including an inability to lift arms for more than a few seconds, loss of ability to show facial expressions and serious speech impediments. These symptoms cause many people affected by FSHD to become dependent on the use of a wheelchair for mobility. Currently, there are no approved treatments for people living with FSHD. About AvidityAvidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X. Forward-Looking StatementsAvidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Avidity's plans to file a BLA for accelerated approval of del-brax and the timing thereof; the potential for del-brax to achieve accelerated approval from the FDA; the status of accelerated approval as a regulatory pathway for del-brax; the use of KHDC1L as the primary endpoint in the FORTITUDE™ biomarker cohort; topline data from the biomarker cohort of the FORTITUDE trial and the timing thereof; characterization of data from the FORTITUDE trial; the potential for del-brax to improve the lives of people with FSHD; the status of the FORTITUDE trial and the cohorts therein and the FORWARD™ trial, including without limitation progress, initiation, enrollment, design, goals and dosage levels and frequencies. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Avidity's business and beyond its control, including, without limitation: the data and results produced from the FORTITUDE trial as of the most recent cutoff dates may not be indicative of final results, may not support BLA submission or accelerated approval, may not be satisfactory to the FDA and other regulators, and new analyses of existing data and results may produce different conclusions than established as of the date hereof; data delivered to the FDA may not support accelerated approval pathways or BLA submissions and may not be satisfactory to the FDA, including as a result of our inability to establish that a novel biomarker may serve as a surrogate endpoint reasonably likely to predict a clinical benefit; even if approved, Avidity may not be able to execute any successful product launches; unexpected adverse side effects to, or inadequate efficacy of, del-brax that may delay or limit its development, regulatory approval and/or commercialization; later developments with the FDA and other global regulators that could be inconsistent with the feedback received to date; Avidity's approach to the discovery and development of product candidates based on its AOC™ platform is unproven and may not produce any products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of clinical trials; Avidity's dependence on third parties in connection with clinical testing and product manufacturing; legislative, judicial and regulatory developments in the United States and foreign countries; Avidity could exhaust its available capital resources sooner than it currently expects; and other risks described in Avidity's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings with the SEC. Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that arise after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contact:Kat Lange(619) 837-5014investors@ Media Contact:Kristina Coppola(619) 837-5016media@ View original content to download multimedia: SOURCE Avidity Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The £100,000 facelift that's knocked years off Kris Jenner at 69
The £100,000 facelift that's knocked years off Kris Jenner at 69

Yahoo

time03-06-2025

  • Yahoo

The £100,000 facelift that's knocked years off Kris Jenner at 69

Everybody loves a transformation story. Had Grease been written in 2025, however, Olivia Newton John would have had to do a lot more than shuck on a biker jacket and a pair of Spandex trousers to make an impact. In a world where billions are vying for attention by ever more desperate means, transformations are two a penny. These days, no diet, makeover or wardrobe glow-up in the world can compete with the impact of a really good facelift. We all know Ozempic can make us thin, and that a stylist can help us dress better. But turning back the years to look 10 years younger? That's still a mystery; a cloak-and-dagger affair whose dark magic occurs behind closed doors, by unknown hands, at unknown cost, with unknown pain and recovery time. Which is likely why so many women can talk of little else these days than Kris Jenner. From the cruise shows of Avignon and Rome to the restaurants of Mayfair to the beach bars of Ibiza, the chat is the same: how, exactly, did the 69-year-old matriarch of the Kardashian clan get her dewy, youthful, plump-yet-taut new visage? And where can we get one? While most women might buy some new clothes to wear to a hen weekend, Kris Jenner went out and bought a new face. When the hen weekend is thrown by Jeff Bezos' soon-to-be-bride Lauren Sanchez, and takes place in Paris, perhaps a Me+Em dress doesn't cut it. No matter that Sanchez, Katy Perry, Eva Longoria and Kim Kardashian were dressed up in their finest garb: they may as well have worn Shein. All eyes were fixated upon Jenner. 'She looks just like Kim!' the internet exclaimed. Which she did – despite being a quarter of a century older. On Tiktok, the hashtag #krisjennernewface has been trending ever since Jenner unveiled her new look, with 57.5 million posts and counting. How-to videos abound, with everyone from surgeons to influencers to your auntie Karen chipping in with their opinions. 'She looks like she's fresh out of the womb,' says the influencer GK Barry, in a post that's had 468.9K views. 'What kind of freaky sorcery is this?' says another user. 'Who is this surgeon, because they are an artist.' The 'artist' in question is Dr Steven Levine, the New York-based surgeon beloved by A-listers for his natural-looking facial enhancements. In a statement shared by Page Six, Levine's representatives confirmed him as the surgeon behind Jenner's most recent work, though they didn't give further details about the procedures. Which hasn't stopped people from speculating. While most celebrities are understandably tight-lipped about the work they've had done, Jenner has previously been open about going under the knife, with one of her procedures even being documented on an episode of Keeping Up With The Kardashians. It's believed that this is Jenner's fifth surgery: as for what she's had done, that depends on who you ask. 'To achieve this sort of transformation in someone who is in their late 60s would likely require a deep plane face and neck lift, blepharoplasty and fat grafting to address lower face jowling and laxity in the neck area,' claims Dr Jonny Betteridge, founder of JB Aesthetics in Mayfair, London. 'This is likely revision surgery, as she would have had surgery in previous years.' According to leading plastic surgeon Patrick Mallucci, Jenner's rejuvenated face has made an impact on account of being unusually well-balanced. 'Looking at her before and after pictures, it appears she's had a brow lift, possibly her upper eyelids operated on, and a very well-done facelift, possibly a deep plane, though it's very difficult to tell the technique by looking at a picture,' he surmises. 'When you look at the thirds of her face – the upper, middle and lower – she's got a very nice, balanced jawline. Unlike some of the facelifts of 20 years ago, where people looked very obviously overpulled and overtightened, this really brings out her good features.' Mallucci's clinic in South Kensington, London, has seen a 30 per cent increase in facelift enquiries over the last five years, as the stigma of 'going under the knife' wanes, and procedures improve in terms of results and recovery time. 'While non-surgical treatments can complement face lifting and stave off the knife until later, ultimately there comes a time when only a facelift can truly rejuvenate an ageing face requiring anatomical improvement,' he says. The 'Rolls Royce' of these is the deep plane. Where a traditional facelift tightens the skin, a deep plane lifts and repositions deeper layers of facial tissue, including sagging muscles and fat, allowing for more natural-looking results which are also longer-lasting. A traditional facelift typically lasts five to seven years: a deep plane can last for up to fifteen. Their subtle results have made 'guess the deep plane' the internet's favourite parlour game, with Nicole Kidman, Anne Hathaway and Lindsey Lohan all recently being cited as allegedly having had the procedure, though this is pure speculation. For her part, Lohan says her appearance is thanks to a healthy diet and laser treatments. Celebrities who have admitted to having deep plane facelifts include the socialite Caroline Stanbury (who had hers aged 49) and the designer Marc Jacobs (who had his at 58). 'There is no such thing as an ideal age for a deep plane facelift, but over the age of 40-45 would generally make a great candidate,' notes the consultant plastic surgeon Mark Solomos. 'You can actually do a deep plane endoscopic facelift at the age of 35 without any obvious scars in front of the ear.' Nor does any previous work tend to be a barrier. 'The only things that would matter would be treatments such as Sculptra. Hyaluronic fillers don't matter too much unless you've overdone it, likewise excessive radio frequency, which tends to burn the fat and creates problems in the subcutaneous tissue.' As for whether 'the Kris effect' means surgeons should now be braced for a wave of clients wanting to look not 10 but 30 years younger than their age, Dr Mallucci believes that managing expectations is key. 'It's very important that I understand what it is that my patients are looking for, but it's equally important that I communicate to them what's realistically achievable. Promising results which are not surgically achievable serves no purpose and only causes disappointment.' And also a depleted bank balance. While a deep plane facelift typically costs between £25,000 – £60,000, it's estimated that the bill for Kris Jenner's work cost in the region of £100,000. Small change for the world's most successful 'momager', but a prohibitively eye-watering amount for most. When your life is lived through a long lens, in the pressure cooker that is Hollywood, it takes more than 'lots of water' to look your best. For better or for worse, the six figure facelift era starts here. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Baker Tilly and MediSpend Expand compliance NOW suite with Launch of stewardship NOW to Transform Life Sciences Compliance
Baker Tilly and MediSpend Expand compliance NOW suite with Launch of stewardship NOW to Transform Life Sciences Compliance

Business Wire

time02-06-2025

  • Business Wire

Baker Tilly and MediSpend Expand compliance NOW suite with Launch of stewardship NOW to Transform Life Sciences Compliance

CHICAGO--(BUSINESS WIRE)--Building on its collaboration with MediSpend, leading advisory, tax and assurance firm Baker Tilly announces the expansion of its healthcare compliance platform, compliance NOW, with the launch of stewardshipNOW, a comprehensive compliance solution that streamlines external funding management for life sciences organizations. Powered by MediSpend, and building off of the success of engagementNOW, stewardship NOW automates the administration of grants, charitable contributions, sponsorships and investigator-initiated research funding. The solution helps life sciences companies align healthcare funding initiatives with corporate values while meeting evolving regulatory requirements. With configurable workflows, customizable portals and robust compliance oversight, stewardship NOW simplifies funding processes from submission through payment execution and reconciliation. 'stewardship NOW empowers life sciences companies to manage the complexities with external funding in a compliant, ethical and efficient way,' said Darren Jones, Baker Tilly principal, life sciences consulting. 'Our collaboration with MediSpend combines strategic insight with advanced technology, helping organizations reduce administrative burden, mitigate risk and execute their funding strategies with confidence and integrity.' Life sciences organizations rely on solutions like stewardship NOW to manage programs for continuing medical education, charitable contributions, corporate sponsorships and patient advocacy funding. Baker Tilly supports organizations in developing global philanthropy strategies, implementing robust compliance controls and driving impactful funding initiatives that respect recipient independence and align with corporate values. 'stewardship NOW marks an important next step in our continued collaboration with Baker Tilly, bringing together our built for purpose technology along with their advisory experience to help life sciences organizations more effectively create and run efficient, transparent and compliant funding programs.' said Seth Houston, Chief Commercial Officer at MediSpend. 'We're excited to continue our collaboration with Baker Tilly to support our shared clients as they make impactful contributions to the healthcare industry.' Baker Tilly and MediSpend together deliver technology-enabled solutions that help life sciences organizations navigate complex global regulations, reduce risk and improve operational efficiency. The firm's complianceNOW suite also includes: transparency NOW – A user-friendly platform that streamlines data capture, collection and reporting while helping organizations stay ahead of evolving regulations. engagement NOW – A comprehensive solution for managing engagements and interactions with healthcare professionals. kol NOW – An on-demand, self-service portal that streamlines the process of evaluating the expertise of key opinion leaders (KOLs) used in consulting engagements. fmv NOW – Direct, self-service access to fair market value (FMV) hourly rates across key opinion leader (KOL) tiers, serving as the delivery mechanism for fair market value rate analysis. For more information about Baker Tilly's compliance NOW solutions, visit: # # # About Baker Tilly ( Baker Tilly is a leading advisory, tax and assurance firm, providing clients with a genuine coast-to-coast and global advantage in major regions of the U.S. and in many of the world's leading financial centers – New York, London, San Francisco, Los Angeles, Chicago and Boston. Baker Tilly Advisory Group, LP and Baker Tilly US, LLP (Baker Tilly) provide professional services through an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations and professional standards. Baker Tilly US, LLP is a licensed independent CPA firm that provides attest services to its clients. Baker Tilly Advisory Group, LP and its subsidiary entities provide tax and business advisory services to their clients. Baker Tilly Advisory Group, LP and its subsidiary entities are not licensed CPA firms. Baker Tilly Advisory Group, LP and Baker Tilly US, LLP, trading as Baker Tilly, are independent members of Baker Tilly International, a worldwide network of independent accounting and business advisory firms in 143 territories, with 43,500 professionals and a combined worldwide revenue of $5.62 billion. Visit or join the conversation on LinkedIn, Facebook and Instagram. MediSpend's best-in-class solutions empower life sciences companies to grow their business compliantly through top-rated solutions and client services. MediSpend provides commercial compliance solutions for the largest pharmaceutical, medical device and dental companies as well as emerging biotech companies across the world. © Baker Tilly Advisory Group, LP

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store